Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

Core Viewpoint - Guardant Health, Inc. has received FDA approval for Guardant360® CDx as a companion diagnostic for identifying patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from BRAFTOVI® treatment [1] Company Summary - Guardant Health, Inc. is recognized as a leading precision oncology company [1] - The FDA's accelerated approval allows for the use of Guardant360® CDx in conjunction with BRAFTOVI® (encorafenib) and cetuximab, along with chemotherapy [1]